Antipsychotic polypharmacy: Never say never, but never say always

Acta Psychiatrica Scandinavica

Volumn 125, Issue 5, 2012, Pages 349-351

  Stahl, Stephen M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; DOPAMINE 2 RECEPTOR; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT;

CONSENSUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TREATMENT FAILURE; EDITORIAL; EMOTIONAL DISORDER; EVIDENCE BASED PRACTICE; HUMAN; MENTAL PATIENT; MONOTHERAPY; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; POLYPHARMACY; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 84859834842     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2012.01841.x     Document Type: Editorial

References (23)

1. Langle G, Steinert T, Weiser P et al. Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr Scand 2012;125:372-381.
2. Stahl SM. Antipsychotic polypharmacy, part I: therapeutic option or dirty little secret? J Clin Psychiatry 1999;60:425-426.
3. Stahl SM. Antipsychotic polypharmacy, part 2: tips on use and misuse. J Clin Psychiatry 1999;60:506-507.
4. Stahl SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry 2002;63:93-94.
5. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Cur Med Chem, 2004;11:313-326.
6. Stahl SM. Focus: antipsychotic polypharmacy - evidence based prescribing or prescribing based evidence? Int J Neuropsychopharmacol 2004;7:113-116.
7. Stahl SM, Grady M. High cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv 2004;57:127-129.
8. Stahl SM. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand 2002;106:321-322.
9. Stahl SM, Freudenreich O, Goff DC. A successful antipsychotic combination trial. Quo Vadis? Acta Psychiatr Scand 2004;110:241-242.
10. Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of pharmaco epidemiological studies. Acta Psychiatr Scand 2010;121:4-10.
11. Nielsen J, Le Quach P, Emborg C, Foldager L, Correll CU. 10year trends in the treatment and outcomes of patients with first episode schizophrenia. Acta Psychiatr Scand 2010;122:356-366.
12. Baandrup L, Allerup P, Lublin H, Nordentoft M, Peacock L, Glenthoj B. Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out patients. Acta Psychiatr Scand 2010;122:367-374.
13. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta analysis of randomized controlled trials. Schizophr Bull 2009;35:443-457.
14. Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R. Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 2001;158:311-314.
15. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cariac death. N Engl J Med 2009;360:225-235.
16. Essock SM, Schooler NR, Stroup TS et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011;168:702-708.
17. Stahl SM, Davis RL. Measuring outcomes and ensuring success. In: Stahl SM, Davis RL, eds. Best practices for medical Teaching. New York: Cambridge University Press, 2011: 117-143.
18. Stahl SM. Case 12, the scary man with only partial symptom control on clozapine. in case studies: Stahl's essential psychopharmacology. New York: Cambridge University Press, 2011, 129-132.
19. Stahl SM. Case 21, the woman who has always been out of control, in case studies: Stahl's essential psychopharmacology. New York: Cambridge University Press, 2011, 237-240.
20. Stahl SM. Case 27, the psychotic arsonist who burned his house and tried to burn himself, in case studies: Stahl's essential psychopharmacology. New York: Cambridge University Press, 2011, 309-314.
21. Stahl SM. Case 39, the psychotic sex offender with grandiosity and mania, in case studies: Stahl's essential psychopharmacology. New York: Cambridge University Press, 2011, 451-456.
22. Stahl SM. How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. Acta Psychiatr Scand 2010;122:440-441.
23. Davies S, Westin A, Castberg I et al. Characterization of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta Psychiatr Scand 2010;122:444-463.